Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 3 trial of TAS-116 in advanced GIST
jRCT2080224033Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing TAS-116 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Sep 2018; status: completed.
02
Drugs
pimitespib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2080224033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224033.